Ру O’z Ўзб Eng
+998 71 228-06-96

+998 78 120-16-61

1002
not found
Кенгайтирилган қидирув
    Press-service

    News

    not found

    Proposals on healthcare reviewed

    On November 14, President Shavkat Mirziyoyev got acquainted with a presentation of proposals on early detection and effective treatment of diseases. In Uzbekistan’s social policy, much attention is paid to healthcare. Over the past seven years, the amount of funds allocated to this area has increased sixfold. More than 400 high-tech operations, which were previously carried out only in Tashkent, are now performed in the regions and districts. To detect diseases early, oncology, endocrinology, and cardiology centers conduct screening examinations in the regions. For example, 1 million 700 thousand women were screened, and 49 thousand were diagnosed with precancerous diseases. In the first half of this year, 122 thousand people were diagnosed with cardiovascular diseases and diabetes at an early stage. Popular health protection is a continuous process. Based on the analysis and needs in the area, proposals have been prepared in essential areas. This was discussed at the presentation. One of the main problems in treatment is the late detection of the disease. Therefore, at the initiative of the President of Uzbekistan, a bonus of 2 million UZS for each case of early detection of oncological diseases was introduced in Kashkadarya as an experiment. As a result, family doctors identified such signs in 51 women and children in the assigned mahallas. 102 million UZS in bonuses were allocated for this, which saved 8 billion UZS that would have been required for treatment if the disease had been detected late. According to the analysis, on average, 20-25 percent of all oncological diseases are breast and uterine cancer. In this regard, it is planned to expand screenings and maintain a registry. Also, this year, three-year programs for the early detection and treatment of hematological, cardiological, and endocrinological diseases will be completed. Responsible persons have been instructed to analyze the achieved results and consider the possibility of extending these programs. The centralized procurement of medicines for medical institutions has shortcomings. Some hospitals have purchased fewer drugs than required, while others have an excess. In this regard, a system for purchasing medicines and medical devices based on fifteen-month demand is proposed. At the same time, the needs for subsequent years will be formed no later than August 1, simultaneously with the parameters of the State Budget. Also, a Procurement Center and its 13 regional branches will be created under the Ministry of Health. From January 1, 2025, the center can purchase original medicines and consumables for closed-type laboratory equipment directly from manufacturers. Another proposal expands donor support. In particular, the one-time cash reward for holders of the “Honorary Donor of the Republic of Uzbekistan” badge is increased from 5 to 15 basic calculation units. They will also be granted the right to free use of public transport and out-of-turn treatment in state sanatoriums. The introduction of the new system is scheduled for January 1 next year. The issue of introducing a procedure for informing the World Trade Organization about sanitary and phytosanitary measures applied in the country was also considered.

    • 15 November, 09:00
    • Read more
    not found

    US FDA approves AstraZeneca's self-administered nasal spray flu vaccine

    The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for self-administration, making it the first of its kind. FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the regulator said. The flu is a common and contagious respiratory disease caused by influenza viruses that typically circulates in the U.S. during the fall and winter. AstraZeneca plans to make the vaccine available through a third-party online pharmacy. Customers will have to complete a screening and eligibility assessment when they order FluMist. The approval provides a new option for receiving a safe and effective seasonal influenza vaccine potentially with greater convenience, flexibility and accessibility for individuals and families, said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research. The vaccine, which was first approved in 2003 to be administered only by healthcare providers, contains a weakened form of live influenza virus strains and is sprayed in the nose. According to the U.S. Centers for Disease Control and Prevention, the flu has resulted in approximately 9.3 million to 41 million illnesses, 100,000 to 710,000 hospitalizations, and 4,900 to 51,000 deaths annually between 2010 and 2023. The FDA said individuals between two and 17 years old should not self-administer FluMist, they should get it from a caregiver instead.

    • 23 September, 09:45
    • Read more
    not found

    New global guidance aims to curb antibiotic pollution from manufacturing

    The World Health Organization (WHO) has published its first-ever guidance on antibiotic pollution from manufacturing. The new guidance on wastewater and solid waste management for antibiotic manufacturing sheds light on this important but neglected challenge ahead of the United Nations General Assembly (UNGA) High-Level Meeting on antimicrobial resistance (AMR) taking place on 26 September 2024. The emergence and spread of AMR caused by antibiotic pollution could undermine the effectiveness of antibiotics globally, including the medicines produced at the manufacturing sites responsible for the pollution. Despite high antibiotic pollution levels being widely documented, the issue is largely unregulated and quality assurance criteria typically do not address environmental emissions. In addition, once distributed, there is a lack of information provided to consumers on how to dispose of antibiotics when they are not used, for example, when they expire or when a course is finished but there is still antibiotic left over. “Pharmaceutical waste from antibiotic manufacturing can facilitate the emergence of new drug-resistant bacteria, which can spread globally and threaten our health. Controlling pollution from antibiotic production contributes to keeping these life-saving medicines effective for everyone," said Dr Yukiko Nakatani, WHO Assistant Director-General for AMR ad interim. Globally, there is a lack of accessible information on the environmental damage caused by manufacturing of medicines. “The guidance provides an independent and impartial scientific basis for regulators, procurers, inspectors, and industry themselves to include robust antibiotic pollution control in their standards,” said Dr Maria Neira, Director, Department of Environment, Climate Change and Health, WHO. “Critically, the strong focus on transparency will equip buyers, investors and the general public to make decisions that account for manufacturers’ efforts to control antibiotic pollution.”  A range of international bodies have called for this guidance, including the WHO Executive Board, the G7 health ministers and UNEP. “The role of the environment in the development, transmission and spread of antimicrobial resistance needs careful consideration since evidence is mounting. There is a widespread agreement that action on the environment must become more prominent as a solution. This includes pollution prevention and control from municipal systems, manufacturing sites, healthcare facilities and agri-food systems,” said Jacqueline Alvarez, Chief of Branch for the Industry and Economy Division at the United Nations Environment Programme (UNEP). The guidance was developed in close collaboration with a diverse group of international experts representing academia, regulators, inspectors, international organizations such as UNEP, and other sectors. The draft also underwent public consultation, receiving valuable input from industry and other stakeholders. Industry has also taken up this challenge, though a voluntary industry-led initiative which can be updated in some areas to align with the new guidance.  The guidance provides human health-based targets to reduce the risk of emergence and spread of AMR, as well as targets to address risks for aquatic life caused by all antibiotics intended for human, animal or plant use. It covers all steps from the manufacturing of active pharmaceutical ingredients (APIs) and formulation into finished products, including primary packaging. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to medicines, making people sicker and increasing the risk of spread of infections that are difficult to treat, illness and deaths. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobial medicines.  

    • 6 September, 09:00
    • Read more
    not found

    15:00 / 04.09.2024

    Global cancer cases to rise by more than 75% by 2050, WHO predicts

    not found

    15:02 / 06.08.2024

    Calculate your personal long COVID risk

    not found

    12:00 / 24.07.2024

    WHO updated recommendations for HIV testing

    not found

    11:55 / 18.07.2024

    WHO issues “rapid communication” on treatment for drug-resistant tuberculosis and hepatitis C

    not found

    12:00 / 12.07.2024

    How to avoid PFAS: 5 common items to avoid to minimise exposure to 'forever chemicals'

    not found

    11:55 / 10.07.2024

    WHO: Talc may cause cancer in humans

    Нажмите на кнопку ниже, чтобы прослушать текст Powered by GSpeech